Welcome to our dedicated page for Scisparc news (Ticker: SPRC), a resource for investors and traders seeking the latest updates and insights on Scisparc stock.
SciSparc Ltd. (SPRC) is a clinical-stage pharmaceutical innovator developing cannabinoid-based therapies for neurological disorders while operating a consumer hemp products division. This page provides verified updates on both business segments, serving investors and stakeholders with essential news repository.
Access authoritative information on SPRC's clinical trial advancements, regulatory filings, and financial performance alongside developments in its hemp-derived product line. Content includes press releases detailing research milestones, partnership announcements, and strategic initiatives across therapeutic and consumer markets.
Key updates cover FDA communications, intellectual property developments, quarterly earnings disclosures, and operational expansions. All materials are curated to meet investor needs for decision-making clarity while maintaining compliance with financial reporting standards.
Bookmark this resource for streamlined access to SPRC's official announcements and analysis. Regularly updated content ensures stakeholders stay informed about the company's progress in pharmaceutical innovation and consumer market execution.
SciSparc Ltd. (NASDAQ: SPRC), a clinical-stage pharmaceutical firm, filed its annual report on Form 20-F for the fiscal year 2021 with the SEC on May 2, 2022. Key achievements include the issuance of a U.S. patent for its technology targeting central nervous system disorders, recruitment of the first patient for a Phase IIa trial of SCI-110 in Alzheimer's, and progress in a Phase IIb trial for Tourette syndrome. The company also formed collaborations to develop psychedelic-based pharmaceuticals and entered a joint venture focused on drug discovery for cancer and infectious diseases.
SciSparc Ltd. (NASDAQ: SPRC), a clinical-stage pharmaceutical company, announced the completion of a joint venture agreement with MitoCareX Bio Ltd. to develop therapies targeting cancer and life-threatening conditions. SciSparc invested $700,000 of a planned $1.7 million, aiming for 50.01% ownership. MitoCareX will explore mitochondrial carriers, crucial for cell viability, to address various health issues. The development builds on successful trials in the UK. This strategic move reflects SciSparc's commitment to enhancing its portfolio in cannabinoid pharmaceuticals and addressing central nervous system disorders.
SciSparc Ltd. (NASDAQ: SPRC) has appointed Prof. Avi Schroeder to its Scientific Advisory Board to enhance the formulation development of its investigational pain treatment, SCI-160. The drug has shown positive results in pre-clinical trials for both acute and chronic pain. Prof. Schroeder brings extensive experience in targeted drug delivery and has made significant contributions to nanotechnology and medicine. The company plans to initiate the Pre-IND process later this year, aiming for an FDA IND Phase I study application.
SciSparc Ltd. (NASDAQ: SPRC) announced the formation of a joint venture, MitoCareX Bio Ltd., to focus on discovering and developing drugs for cancer and other serious conditions. The new Israeli-based company will explore the role of mitochondrial carriers in treating life-threatening diseases. SciSparc plans to invest up to $1.7 million over two years for a 50.01% stake, contingent on specific milestones. The initiative aims to leverage advanced drug discovery techniques and prior successful experiments in the UK, with expert Professor Ciro Leonardo Pierri advising the program.
SciSparc Ltd. (NASDAQ: SPRC), a clinical-stage pharmaceutical company, will present at the Aegis Capital Corp. Virtual Conference on February 24, 2022, at 8:30 a.m. EST. The conference runs from February 23-25, 2022. Interested parties can access the presentation by requesting it from Aegis during the conference dates. The slide deck will also be available on SciSparc's website. The company is focused on cannabinoid pharmaceuticals, with drug development programs targeting disorders such as Tourette syndrome, obstructive sleep apnea, and autism.
SciSparc Ltd. (NASDAQ: SPRC) announced a new leadership team effective January 10, 2022. Oz Adler has been appointed CEO, while Itschak Shrem becomes President and Amitay Weiss is named Chairman of the Board. Adler has been with the company since September 2017, serving as CFO since April 2018. Weiss joined in August 2020, previously working at Bank Poalei Agudat Israel Ltd. Shrem has been Chairman since August 2020 and has extensive experience in financial markets. SciSparc focuses on developing cannabinoid-based pharmaceuticals for conditions like Tourette syndrome and Alzheimer's disease.
SciSparc Ltd. (NASDAQ: SPRC) has announced an agreement with Hannover Medical School and Tel-Aviv Sourasky Medical School to advance its Phase IIb clinical study for SCI-110, a drug aimed at treating Tourette syndrome. The study will be led by renowned experts and is a double-blind, placebo-controlled trial evaluating SCI-110's efficacy and safety for adults aged 18-65. SCI-110 combines dronabinol with palmitoylethanolamide and is developed to enhance THC effectiveness while reducing side effects. The study aims to address the unmet medical need for effective treatments in Tourette syndrome, a condition affecting approximately 1% of the global population.
SciSparc Ltd. (NASDAQ: SPRC) has initiated an examination of psychedelic compounds as potential additions to its intellectual property portfolio. The growing interest in psychedelics could align with the company's focus on disorders of the central nervous system. A report suggests the psychedelic therapy market may reach over $10 billion by 2027, up from $4.75 billion in 2020. Chief Technologies Officer Adi Zuloff-Shani expressed optimism about the compatibility of psychedelic compounds with the company's existing drug development programs, which target conditions such as Tourette syndrome and Alzheimer's disease.
SciSparc Ltd. (NASDAQ: SPRC) announced the recruitment of its first patient for a Phase IIa clinical trial investigating the safety, tolerability, and efficacy of SCI-110 in treating Alzheimer's disease and associated agitation. Conducted at the Israeli Medical Center for Alzheimer's, the trial aims to provide an efficient treatment option amid limited existing therapies. SCI-110 combines synthetic Δ⁹-THC and Palmitoylethanolamide to address behavioral disturbances commonly observed in Alzheimer's patients, with the hope of improving their quality of life.
SciSparc Ltd. (NASDAQ: SPRC) announced a significant milestone with the granting of U.S. Patent No. 11,207,290, covering cannabinoid and N-acylethanolamine combinations for treating central nervous system disorders. This achievement is deemed crucial for the company, as it strengthens their intellectual property portfolio, now comprising four U.S. patents, along with similar patents in Australia and Japan. The patent emphasizes the uniqueness of their methodologies and compounds, reinforcing SciSparc's commitment to developing effective treatments for patients facing currently untreatable conditions.
FAQ
What is the current stock price of Scisparc (SPRC)?
What is the market cap of Scisparc (SPRC)?
